ChenGuang Biotech Group Co., Ltd. (300138.SZ)
CNY 10.79
(-2.79%)
CNY 10.79
(-2.79%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.88 Billion CNY | 31.81% |
| 2022 | 3.7 Billion CNY | 16.96% |
| 2021 | 3.17 Billion CNY | 22.23% |
| 2020 | 2.59 Billion CNY | -6.18% |
| 2019 | 2.76 Billion CNY | 71.07% |
| 2018 | 1.61 Billion CNY | 29.47% |
| 2017 | 1.24 Billion CNY | 29.09% |
| 2016 | 967.45 Million CNY | 71.5% |
| 2015 | 564.11 Million CNY | 12.89% |
| 2014 | 499.69 Million CNY | -22.08% |
| 2013 | 641.26 Million CNY | 43.23% |
| 2012 | 447.72 Million CNY | 204.24% |
| 2011 | 147.16 Million CNY | -31.84% |
| 2010 | 215.91 Million CNY | 12.36% |
| 2009 | 192.17 Million CNY | -19.02% |
| 2008 | 237.3 Million CNY | 177.57% |
| 2007 | 85.49 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 5.66 Billion CNY | 15.8% |
| 2024 Q2 | 5.04 Billion CNY | -10.88% |
| 2024 Q3 | 4.64 Billion CNY | -8.03% |
| 2023 Q2 | 3.77 Billion CNY | -11.6% |
| 2023 Q1 | 4.27 Billion CNY | 15.24% |
| 2023 Q3 | 3.87 Billion CNY | 2.49% |
| 2023 Q4 | 4.88 Billion CNY | 26.23% |
| 2023 FY | 4.88 Billion CNY | 31.81% |
| 2022 FY | 3.7 Billion CNY | 16.96% |
| 2022 Q2 | 3.2 Billion CNY | -2.39% |
| 2022 Q3 | 3.37 Billion CNY | 5.19% |
| 2022 Q4 | 3.7 Billion CNY | 9.91% |
| 2022 Q1 | 3.28 Billion CNY | 3.65% |
| 2021 Q3 | 1.44 Billion CNY | -22.78% |
| 2021 FY | 3.17 Billion CNY | 22.23% |
| 2021 Q2 | 1.86 Billion CNY | -11.82% |
| 2021 Q1 | 2.11 Billion CNY | -18.34% |
| 2021 Q4 | 3.17 Billion CNY | 119.82% |
| 2020 Q2 | 2.81 Billion CNY | 3.25% |
| 2020 Q3 | 2.16 Billion CNY | -23.06% |
| 2020 FY | 2.59 Billion CNY | -6.18% |
| 2020 Q4 | 2.59 Billion CNY | 20.01% |
| 2020 Q1 | 2.72 Billion CNY | -1.59% |
| 2019 Q2 | 1.51 Billion CNY | -4.64% |
| 2019 FY | 2.76 Billion CNY | 71.07% |
| 2019 Q3 | 1.61 Billion CNY | 6.58% |
| 2019 Q4 | 2.76 Billion CNY | 71.21% |
| 2019 Q1 | 1.58 Billion CNY | -1.69% |
| 2018 Q3 | 1.25 Billion CNY | -2.82% |
| 2018 Q1 | 1.23 Billion CNY | -0.96% |
| 2018 FY | 1.61 Billion CNY | 29.47% |
| 2018 Q4 | 1.61 Billion CNY | 28.65% |
| 2018 Q2 | 1.29 Billion CNY | 4.55% |
| 2017 Q3 | 536.76 Million CNY | -36.7% |
| 2017 Q4 | 1.24 Billion CNY | 132.67% |
| 2017 FY | 1.24 Billion CNY | 29.09% |
| 2017 Q1 | 856.23 Million CNY | -11.5% |
| 2017 Q2 | 848.02 Million CNY | -0.96% |
| 2016 Q4 | 967.45 Million CNY | 103.73% |
| 2016 Q3 | 474.87 Million CNY | 9.62% |
| 2016 Q2 | 433.19 Million CNY | -18.44% |
| 2016 FY | 967.45 Million CNY | 71.5% |
| 2016 Q1 | 531.13 Million CNY | -5.85% |
| 2015 Q1 | 488.29 Million CNY | -2.28% |
| 2015 Q3 | 354.23 Million CNY | 1.02% |
| 2015 FY | 564.11 Million CNY | 12.89% |
| 2015 Q4 | 564.11 Million CNY | 59.25% |
| 2015 Q2 | 350.65 Million CNY | -28.19% |
| 2014 Q2 | 471.5 Million CNY | -25.59% |
| 2014 Q4 | 499.69 Million CNY | 50.25% |
| 2014 Q3 | 332.57 Million CNY | -29.46% |
| 2014 Q1 | 633.63 Million CNY | -1.19% |
| 2014 FY | 499.69 Million CNY | -22.08% |
| 2013 Q2 | 459.96 Million CNY | -13.35% |
| 2013 FY | 641.26 Million CNY | 43.23% |
| 2013 Q4 | 641.26 Million CNY | 35.17% |
| 2013 Q3 | 474.41 Million CNY | 3.14% |
| 2013 Q1 | 530.79 Million CNY | 18.55% |
| 2012 Q3 | 292.14 Million CNY | 20.01% |
| 2012 Q4 | 447.72 Million CNY | 53.26% |
| 2012 Q1 | 201.4 Million CNY | 36.86% |
| 2012 FY | 447.72 Million CNY | 204.24% |
| 2012 Q2 | 243.42 Million CNY | 20.86% |
| 2011 Q1 | 206.98 Million CNY | -4.14% |
| 2011 Q2 | 143.04 Million CNY | -30.89% |
| 2011 Q4 | 147.16 Million CNY | 8.34% |
| 2011 FY | 147.16 Million CNY | -31.84% |
| 2011 Q3 | 135.82 Million CNY | -5.04% |
| 2010 Q3 | 214.73 Million CNY | 30.73% |
| 2010 Q4 | 215.91 Million CNY | 0.55% |
| 2010 FY | 215.91 Million CNY | 12.36% |
| 2010 Q2 | 164.25 Million CNY | 0.0% |
| 2009 Q4 | 192.17 Million CNY | 0.0% |
| 2009 FY | 192.17 Million CNY | -19.02% |
| 2008 FY | 237.3 Million CNY | 177.57% |
| 2007 FY | 85.49 Million CNY | 0.0% |